Ocugen Gains Provisional Approval for RP Therapy in Bahamas, Aims for First Patient Treatment in 90 Days
Event summary
- Ocugen's OCU400 received provisional approval and priority designation under the Longevity and Regenerative Therapies Act in The Bahamas.
- The company aims to treat the first retinitis pigmentosa (RP) patient within 90 days following full LARTA approval.
- OCU400 is in Phase 3 trials, with topline data expected in 1Q 2027 and a Biologics License Application planned for 2Q 2027.
- The therapy targets a broad RP indication, addressing mutations caused by over 100 genes.
The big picture
Ocugen's provisional approval in The Bahamas marks a strategic pivot toward expanded access for its modifier gene therapy, OCU400. This move aligns with broader industry trends toward regenerative medicine and global healthcare equity. The company's ability to secure priority designation underscores the clinical promise of OCU400, potentially positioning it as a key player in the treatment of inherited retinal diseases. The success of this initiative will hinge on regulatory cooperation and the therapy's demonstrated efficacy in Phase 3 trials.
What we're watching
- Regulatory Pathway
- Whether the LARTA Priority Designation will expedite full approval and commercialization of OCU400 in The Bahamas.
- Clinical Trial Progress
- The pace at which Phase 3 data for OCU400 will read out in 1Q 2027 and its impact on the Biologics License Application.
- Market Access Strategy
- How Ocugen's commercial pricing model will address global access and unmet need for RP treatment.
Related topics